



November 13, 2014

# CLINICAL PRACTICE CHANGE

## Introduction of Factor XIII Antigen Assay

**Effective November 19, 2014,** the DSM Health Sciences Centre site will change standard testing for clotting Factor XIII to an automated quantitative assay of Factor XIII (subunit A) Antigen.

FXIII testing has been done using the Clot Solubility assay, which measures FXIII function, but only detects severe deficiency (less than 2% FXIII). In contrast, the Factor XIII Antigen assay can determine FXIII protein levels across a range of normal and abnormal values.

The FXIII Antigen assay will now become the standard test for determination of FXIII levels. If the FXIII Antigen level is less than 10%, a Clot Solubility assay will be performed. Results of both assays will be reported.

Reference Intervals: Refer to the LIS report for the reference intervals for FXIII Antigen.

Sample Requirements: Testing must be approved by a Hematologist or Hematopathologist. Sample requirements are unchanged.

Please contact Dr. Sara Israels, Haemostasis Laboratory Director, at 204-787-2105 or sisraels@cancercare.mb.ca with any questions or concerns.



**dsmanitoba.ca**

Suite 1502 – 155 Carlton Street
Winnipeg, Manitoba
R3C 3H8

155, Rue Carlton, suite 1502
Winnipeg (Manitoba)
R3C 3H8

T 204.926.8005
1.866.320.8796 – Toll-free Manitoba only
F 204.940.1761